| 2.33 -0.11 (-4.51%) | 04-25 12:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.59 | 1-year : | 4.34 |
| Resists | First : | 3.08 | Second : | 3.72 |
| Pivot price | 2.59 |
|||
| Supports | First : | 2.04 | Second : | 1.7 |
| MAs | MA(5) : | 2.39  |
MA(20) : | 2.81 |
| MA(100) : | 5.15 |
MA(250) : | 3.77 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 27.1 |
D(3) : | 25.8 |
| RSI | RSI(14): 30 |
|||
| 52-week | High : | 8.47 | Low : | 1.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CASI ] has closed above bottom band by 29.9%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.58 - 2.6 | 2.6 - 2.6 |
| Low: | 2.41 - 2.43 | 2.43 - 2.44 |
| Close: | 2.42 - 2.44 | 2.44 - 2.46 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Wed, 24 Apr 2024
Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Yahoo Finance
Mon, 08 Apr 2024
CASI Pharmaceuticals updates on Juventas dispute By Investing.com - Investing.com
Mon, 08 Apr 2024
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - PR Newswire
Tue, 12 Mar 2024
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26% - Simply Wall St
Sat, 09 Mar 2024
Breakeven Is Near for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Simply Wall St
Tue, 05 Mar 2024
CASI Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 47.4 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 82 (K) |
| Shares Short P.Month | 42 (K) |
| EPS | -2.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | -79.6 % |
| Operating Margin | -50.4 % |
| Return on Assets (ttm) | -18.5 % |
| Return on Equity (ttm) | -57.7 % |
| Qtrly Rev. Growth | -55 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.52 |
| EBITDA (p.s.) | -1.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -1.16 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0.92 |
| Price to Cash Flow | -1.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|